RE:RE:Great opportunity!I agree it isnt without its caveats and concerns. Would I add at higher prices? Definitiely not, I already have enough exposure. However, at these levels it is like salvage value. A few thoughts on the opportunities and partnerships.
- NASH: I feel that the Pandemic really did drag any progress on this. There was risk on top of risk that hampered any partnership. Then there was they delays for the F8 formulation and the human factors study. Total failures in my eyes, but they are expected to resulve through the coming year and perhaps clear the way for a partnership? Again this is a flyer at this point, but at these levels this is not my driver for buying.
- Trogarzo: The IV push should somewhat help sales? Really this is just helping the cashflow case for the company, but there isnt much beyond that here.
- TH1902: The pause absolutely sucks, no question there, but there is still value to the program. Maybe not the slam dunk people had envisioned a few months ago, but there is a path forward. However due to the lack of cash, TH will need to partner in NASH or Oncology to move things forward. This unfortunately removes some upside from current shareholders, but will provide legitamacy and drive short term value.
The way I see it, TH should focus on the shareholder value and speed to market for their programs. If that means partnering or getting boughtout, then lets make the nessesary changes and get it done. With the Marathon Debt, the the clock has started and they cant do the same song and dance they had been for the past 20 years.
Insiders can't buy until earnings are released, so the only tell we will have before then is next week's option expiry. If they don't see value at $0.38 then there needs to be a shake up at all levels.